Pharmacotherapy Publishing Inc
View my basket
Atypon Link logo

You have no access to this article

Challenge and Rechallenge: Drotrecogin alfa (activated)–Induced Prolongation of Activated Partial Thromboplastin Time in a Patient with Severe Sepsis


Author(s): Emily E. Castelli | Colleen M. Culley | Mitchell P. Fink
doi: 10.1592/phco.2005.25.8.1147
Prev | Table of contents | Next
 
View PDF article (52 K) View references
Email this link
 What is RSS?
Trouble viewing articles as PDF?
 
  Pharmacotherapy
 
Print ISSN: 0277-0008
Volume: 25 | Issue: 8
Cover date: August 2005
Page(s): 1147-1150
 
 
  Key words
 
drotrecogin alfa (activated), anticoagulation, sepsis, partial thromboplastin time
 
  Abstract

An 81-year-old woman with ischemic bowel underwent laparotomy with small-bowel resection and developed septic shock. She required broadspectrum antibiotics, norepinephrine, and mechanical ventilation. The patient received drotrecogin alfa (activated) 24 μg/kg/hour for a total of 67.5 hours. Coagulation parameters were monitored during her therapy. Significant increases in activated partial thromboplastin time (aPTT) during infusion led to two temporary discontinuations of the drug. Coagulation parameters decreased when the drug was held and increased with each rechallenge. The patient survived the episode and was discharged on postoperative day 27. Medical records of 26 other patients who received drotrecogin alfa (activated) at our institution from November 2001–August 2003 were reviewed retrospectively for coagulation parameters and bleeding rate. Of the 26 patients, nine (35%) were treatment compliant (> 90% of the 96-hr course). Coagulopathy and bleeding resulted in early discontinuation in four (15%) and six (23%) patients, respectively. An increase in aPTT from baseline to during infusion of drotrecogin alfa (activated) was noted in 14 patients with complete data (p=0.56). A decrease in median platelet count from baseline to during infusion was noted in the six patients who bled during therapy (p=0.01). Two of these patients had platelet counts less than 30 × 103/mm3 during administration. Drotrecogin alfa (activated) should be considered an anticoagulant. In postmarketing reports, clinically significant bleeding occurred more frequently than was noted in a large, randomized, multicenter trial. Patients receiving drotrecogin alfa (activated) should be closely monitored for prolongation of coagulation parameters. Temporary discontinuation of the drug should be considered when international normalized ratio is greater than 3.0, platelet count is less than 15 × 103/mm3, and aPTT is greater than 100 seconds.

 
  Author(s) affiliations
 
1. Departments of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, Pennsylvania.
2. Departments of Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, Pennsylvania.
Address reprint requests to Colleen M. Culley, Pharm.D., BCPS, Department of Pharmacy and Therapeutics, University of Pittsburgh, 302 Scaife Hall, 200 Lothrop Street, Pittsburgh, PA 15213.
3. Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
 
  This article has been cited by:
1.
 
Animal models of sepsis and its complications.
Mitchell P Fink.
Kidney International |  74 |  8 |  991-993
CrossRef